It must be remembered that AD is much more complex than its oversimplification to pathological hallmarks of amyloid plaques, tau tangles and neurodegeneration (termed the ATN biomarker system), and AD clinical trials targeting tau pathology will likely need to take account of this. Here, MAPT is linked to Alzheimer disease.